A bridge between multi-omics data and the management of hepatocellular carcinoma.

Naoshi Nishida; Masatoshi Kudo

doi:10.3978/j.issn.2305-5839.2014.12.01

Abstract

1 min read

Recent technological advancements in comprehensive genome and transcriptome analyses have clarified the molecular pathways underlying the development of human hepatocellular carcinomas (HCCs). However, there is still a gap between the results of multi-omics analyses and their clinical implications. Because of the large quantity of data obtained through these types of analyses, identifying target molecules important for clinical uses is difficult.

Related publications

Article2020

Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma

Naoshi Nishida, Masatoshi Kudo

Dataset

Supplementary Material for: Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1

Naoshi Nishida, Kazuko Sakai, Masahiro Morita, Tomoko Aoki, Masahiro Takita, Shingo Hagiwara, Yoriaki Komeda, Mamoru Takenaka, Yasunori Minami, Hiroshi Ida, Kazuomi Ueshima, K. Nishio, Masatoshi Kudo

Article2017

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, Olga Kuchuk, Carlos Villacorta-Martín, Manuel Castro de Moura, Juan Putra, Genís Campreciós, Laia Bassaganyas, Nicholas K. Akers, Bojan Losic, Samuel Waxman, Swan N. Thung, Vincenzo Mazzaferro, Manel Esteller, Scott L. Friedman, M. Schwartz, Augusto Villanueva, Josep M. Llovet

Gastroenterology

Article2008

Novel advancements in the management of hepatocellular carcinoma in 2008

Josep M. Llovet, Jordi Bruix

Journal of Hepatology

Article2009

Pathogenesis of hepatocellular carcinoma and molecular therapies

Beatriz Mínguez, Victoria Tovar, Derek Y. Chiang, Augusto Villanueva, Josep M. Llovet

Current Opinion in Gastroenterology